Working with Us
Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams rich in diversity. Take your career farther than you thought possible.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us.
A skilled leader and accomplished marketer with customer focus to lead the commercial business for Zeposia in Ulcerative Colitis (UC), which represents a $1.0+ BN peak year sales opportunity in the US and Cendakimab in EoE which has the potential to launch in late 2025. The GI Marketing Lead will lead all aspects of in-line commercialization planning and execution for Zeposia in the treatment of UC and partner with the WW and US commercialization teams to prepare for & launch Cendakimab for EoE. The GI Marketing Lead reports directly to the Vice President, Neurology & GI Sales and Marketing. He or She will be accountable for managing a high-performance team of top talent and staffing, as needed, to develop and execute a full promotional plan to support solidifying Zeposia as the next step in UC therapy to the gastroenterology healthcare community and building a full commercialization launch plan for Cendakimab in EoE. In addition, this individual will lead collaboratively across a matrix organization inclusive of Sales & Sales Training, MAX, Regional Field Marketing, Medical, Customer Insights, Worldwide Commercial, Legal, Promotion Integrity, and our WW Customer Engagement Team. He or She will be accountable for leading the US MS matrix team and will manage, mentor, and coach the team developing and executing plans to deliver sustainable differentiation and accelerated growth of Zeposia in UC and rapid adoption of Cendakimab for EoE.
We are looking for a dynamic, performance-driven leader who cultivates a team-based, collaborative, customer/externally focused environment which promotes candor, innovation, and appropriate risk taking.
Key Responsibilities
Lead development and execution of the US GI strategy and communication platforms for Zeposia and Cendakimab, in collaboration with matrix team, including Worldwide, to ensure synergistic messaging and execution across the brands.
Manage brand/ indication-level operating expense decisions to ensure proper resource utilization across A&P spend and operating expense management.
Drive top-line forecasting and projection workstream for US Zeposia UC indication and Cendakimab US in conjunction with the Business Insights & Analytics team.
Continue to solidify BMS presence and leadership in gastroenterology through the development of a customer focused engagement plan, inclusive of a communication platform, that will clearly & succinctly convey the company’s commitment to GI.
In collaboration with MAX organization, develop and implement comprehensive access strategy and plan, consistent with brand strategy and inclusive of payer access and patient services model.
Identify / retain top marketing talent and build GI professional promotions team.
Effectively analyze customer insights, brand performance, market trends, & competitive response to inform strategic plan which addresses key challenges and capitalizes on prioritized business opportunities
Foster strong, collaborative working relationships with external and internal customers
Collaborate with matrix BI&A team to identify and leverage deep customer insights
Develop and implement the strategic and tactical plans to promote Zeposia and Cendakimab to Healthcare Practitioners
Partner with WW Customer Engagement Team to optimize Marketing Mix & Channel selection.
Lead and mentor GI matrix team to communicate performance and strategy presentations to Leadership Teams
Provide commercial input to optimize the brand’s US data / evidence generation plan
Qualifications & Experience
MBA or another Advanced Degree Preferred.
Minimum of 10 years of pharmaceutical experience with a minimum of 5 years of marketing experience.
Strong leadership skills to lead/contribute to the overall strategic planning and execution of key deliverables
Prior experience managing & developing high performing teams required.
Prior Health Care Practitioner marketing experience with demonstrated expertise in customer focus, insight mining, message development and marketing analytics required.
Proven track record of effectively and efficiently driving performance within a matrix organization with strong organizational, interpersonal, communication skills and executive collaboration required.
Ability to develop and manage strong customer relationships
Immunology experience strongly preferred.
Successful launch experience strongly preferred.
Willing to travel up to 25%
New York, New York
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.
The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.